CoChat

Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

Open access
Leichman, Lawrence, Groshen, Susan, O’Neil, Bert H., Messersmith, Wells, Berlin, Jordan, Chan, Emily, Leichman, Cynthia G., Cohen, Steven J., Cohen, Deirdre, Lenz, Heinz-Josef, Gold, Philip, Boman, Bruce, Fielding, Anitra, Locker, Gershon, Cason, Ronald C., Hamilton, Stan R., Hochster, Howard S. · 2016 · The Oncologist
Cited by 82

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background.: Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor therapy in patients with CRC and inefficient tumor DNA repair mechanisms, such as those with high-level microsatellite instability (MSI-H), would result in synthetic lethality. Methods.: This was an open-label phase II trial testing olaparib 400 mg p.o. b.i.d. for patients with disseminated, measurable CRC failing standard therapies with centrally confirmed tumor MSI status. The primary endpoint was the tumor response, assessed by RECIST, version 1.0. The secondary endpoints were safety/toxicity, progression-free survival (PFS), and overall survival (OS). Results.: Thirty-three patients (20 microsatellite stable [MSS], 13 MSI-H) were enrolled. The median age for all patients was 57 years and for MSS and MSI-H patients was 51 and 61 years, respectively. All patients received at least one 28-day cycle of olaparib. No patient had a complete or partial response. Nausea (48%), fatigue (36%), and vomiting (33%) were the most commonly reported treatment-related adverse events. The median PFS for all patients was 1.84 months. No statistically significant differences were found in the median PFS or OS for the MSS group compared with the MSI-H group. Conclusion.: Single-agent olaparib delivered after failure of standard systemic therapy did not demonstrate activity for CRC patients, regardless of microsatellite status. Future trials, testing PARP inhibitors in patients with CRC should focus on the use of DNA-damaging chemotherapy and/or radiation therapy, combined with PARP inhibitors, remembering the toxicity reported in the present study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2015-0319

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 82

Metadata

Authors
Leichman, L., Groshen, S., O’Neil, B. H., Messersmith, W., Berlin, J., Chan, E., Leichman, C. G., Cohen, S. J., Cohen, D., Lenz, H.-J., Gold, P., Boman, B., Fielding, A., Locker, G., Cason, R. C., Hamilton, S. R., & Hochster, H. S.
Venue
The Oncologist
Published
2016-01-19
Volume
21
Issue
2
Pages
172-177
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2265625172
Cited by
82
References
9
FWCI
2.63
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. https://app.cochat.ai/papers/10.1634/theoncologist.2015-0319
The paper
Leichman, L., Groshen, S., O’Neil, B. H., Messersmith, W., Berlin, J., Chan, E., Leichman, C. G., Cohen, S. J., Cohen, D., Lenz, H.-J., Gold, P., Boman, B., Fielding, A., Locker, G., Cason, R. C., Hamilton, S. R., & Hochster, H. S. (2016). Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. The Oncologist. https://doi.org/10.1634/theoncologist.2015-0319

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.